BioSpace News Archive

IGM Biosciences, Inc., a clinical-stage biotechnology company focused on creating and developing IgM antibodies, announced its financial results for the fourth quarter and full year ended December 31, 2021 and provided an update on recent developments.

ImmunoGen, Inc. announced that it has submitted a Biologics License Application under the accelerated approval pathway to the US Food and Drug Administration for mirvetuximab soravtansine monotherapy in patients with folate receptor alpha -high platinum-resistant ovarian cancer who have been previously treated with 1 to 3 prior systemic treatments.

Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported financial results for the fourth quarter and full year ended December 31, 2021, and provided a corporate update.

Candel Therapeutics, Inc., a late clinical stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies, reported financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update.

T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced that it will host an Analyst and Investor Day on Tuesday, April 12, 2022, at 12:00pm ET.

Nkarta, Inc., a clinical-stage biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, announced the appointment of Angela M. Thedinga, MBA, MPH, to its Board of Directors.

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today reported its financial and operating results for the year ended December 31, 2021.

Aeglea BioTherapeutics, Inc. today announced poster presentations at two upcoming medical meetings.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Reshma Rangwala, MD, PhD, as the Company’s Chief Medical Officer.

VolitionRx Limited, a multi-national epigenetics company, has announced the signing of an exclusive global supply and licensing agreement with Heska Corporation to sell its Nu.Q® Vet Cancer Screening Test at the point of care for companion animals.